101 related articles for article (PubMed ID: 27293069)
1. Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis.
Beauverd Y; Alimam S; McLornan DP; Radia DH; Harrison CN
Br J Haematol; 2016 Oct; 175(1):37-42. PubMed ID: 27293069
[TBL] [Abstract][Full Text] [Related]
2. Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
Kourie HR; Ameye L; Paesmans M; Bron D
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):264-8. PubMed ID: 26935576
[TBL] [Abstract][Full Text] [Related]
3. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
4. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
[TBL] [Abstract][Full Text] [Related]
6. Distinct profile of CD34
Forte D; Barone M; Morsiani C; Simonetti G; Fabbri F; Bruno S; Bandini E; Sollazzo D; Collura S; Deregibus MC; Auteri G; Ottaviani E; Vianelli N; Camussi G; Franceschi C; Capri M; Palandri F; Cavo M; Catani L
J Exp Clin Cancer Res; 2021 Feb; 40(1):49. PubMed ID: 33522952
[TBL] [Abstract][Full Text] [Related]
7. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.
Aguirre LE; Jain A; Ball S; Ali NA; Volpe VO; Tinsley-Vance S; Sallman D; Sweet K; Lancet J; Padron E; Yun S; Kuykendall A; Komrokji R
Clin Lymphoma Myeloma Leuk; 2024 Jul; 24(7):459-467. PubMed ID: 38548563
[TBL] [Abstract][Full Text] [Related]
8. [BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation].
Amemiya A; Ito Y; Ishibashi Y; Saito Y; Katagiri S; Suguro T; Asano M; Yoshizawa S; Akahane D; Tanaka Y; Fujimoto H; Okabe S; Gotoh M; Tauchi T; Ohyashiki K
Rinsho Ketsueki; 2017; 58(4):298-302. PubMed ID: 28484156
[TBL] [Abstract][Full Text] [Related]
9. A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients.
Wassie E; Finke C; Gangat N; Lasho TL; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
Br J Haematol; 2015 Apr; 169(1):71-6. PubMed ID: 25521305
[TBL] [Abstract][Full Text] [Related]
10. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
Lestang E; Peterlin P; Le Bris Y; Dubruille V; Delaunay J; Godon C; Theisen O; Blin N; Mahe B; Gastinne T; Garnier A; Touzeau C; Voldoire M; Bene MC; Le Gouill S; Milpied N; Mohty M; Moreau P; Guillaume T; Chevallier P
Eur J Haematol; 2017 Jul; 99(1):60-69. PubMed ID: 28370306
[TBL] [Abstract][Full Text] [Related]
11. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
[TBL] [Abstract][Full Text] [Related]
12. How I manage anemia related to myelofibrosis and its treatment regimens.
Verstovsek S
Ann Hematol; 2023 Apr; 102(4):689-698. PubMed ID: 36786879
[TBL] [Abstract][Full Text] [Related]
13. Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.
Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Pauwilai T; Singdong R; Rujirachaivej P; Chareonsirisuthigul T; Siriboonpiputtana T
Hematology; 2017 Dec; 22(10):599-606. PubMed ID: 28406068
[TBL] [Abstract][Full Text] [Related]
14. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.
Guglielmelli P; Pancrazzi A; Bergamaschi G; Rosti V; Villani L; Antonioli E; Bosi A; Barosi G; Vannucchi AM; ;
Br J Haematol; 2007 May; 137(3):244-7. PubMed ID: 17408465
[TBL] [Abstract][Full Text] [Related]
15. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.
Pardanani A; Guglielmelli P; Lasho TL; Pancrazzi A; Finke CM; Vannucchi AM; Tefferi A
Leukemia; 2011 Dec; 25(12):1834-9. PubMed ID: 21691276
[TBL] [Abstract][Full Text] [Related]
16. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
17. Myelofibrosis: clinicopathologic features, prognosis, and management.
O'Sullivan JM; Harrison CN
Clin Adv Hematol Oncol; 2018 Feb; 16(2):121-131. PubMed ID: 29741513
[TBL] [Abstract][Full Text] [Related]
18. Prognostication in MF: from CBC to cytogenetics to molecular markers.
Zhou A; Oh ST
Best Pract Res Clin Haematol; 2014 Jun; 27(2):155-64. PubMed ID: 25189726
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
[TBL] [Abstract][Full Text] [Related]
20. Calreticulin mutation profile in Indian patients with primary myelofibrosis.
Sazawal S; Singh N; Mahapatra M; Saxena R
Hematology; 2015 Dec; 20(10):567-70. PubMed ID: 25959795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
